Anavex Life Sciences advances ANAVEX 2-73

Anavex Life Sciences Corp. (Nasdaq: AVXL) will design a double-blinded, randomized, placebo-controlled Phase 2/3 study for its Alzheimer's disease treatment ANAVEX 2-73. The stock price leaped $2.06 to close at $5.30.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.